Experienced in regenerative medicine, Ivan has a strong ability to translate design requirements into actionable plans. Ivan Santos is the Biologics Manufacturing and Operations Manager at Organicell. Ivan Santos Biologics Manufacturing and Operations Manager
Organicell is committed to completing our FDA-approved clinical trials as we hope to develop an FDA-approved treatment option targeted to patients suffering from COVID-19.
Nano sales manager trial trial#
This trial is being conducted to investigate the safety and potential efficacy of intravenous infusion of Zofin™ for the treatment of moderate to severe acute respiratory syndrome (SARS) related to COVID-19. In addition to completing multiple emergency INDs under our parent IND, our multi-center, randomized, double-blinded, placebo-controlled phase I/II clinical trial is actively enrolling. The trial is being conducted at the United Memorial Medical Center in Houston, TX. The expanded access protocol provided access to Zofin for patients in outpatient and inpatient facilities infected with SARS-CoV-2 who have mild to moderate COVID-19 infection, or who are judged by a healthcare provider to be at high risk of progression to moderate disease. Organicell™ is prepared to begin enrollment of our phase I/II expanded access clinical trial using our investigational new drug (IND) and lead product, Zofin™. (OTCQB: OCEL) is the leading clinical-stage biopharmaceutical and regenerative medicine company dedicated to the development of regenerative therapies. This approved trial design will be a double blinded, placebo-controlled, phase I/II trial investigating the safety and potential efficacy of intravenous infusion (IV) of Zofin™ for the treatment of COPD. Food and Drug Administration (FDA) for an Investigational New Drug (IND) application on our lead product, Zofin™, in the treatment of patients diagnosed with COPD. Organicell Regenerative Medicine, Inc., received approval from the U.S.
Chronic Obstructive Pulmonary Disease (COPD) This approved trial design, which will begin in the second quarter of this year, will be a double blinded, placebo-controlled, phase I/II trial investigating the safety and potential efficacy of Zofin™ for patients suffering with knee osteoarthritis. Food and Drug Administration (FDA) for an Investigational New Drug (IND) application on our lead product, Zofin™, in the treatment of knee osteoarthritis. Organicell™ is committed to creating life changing and lifesaving therapies for patients. We believe that our ground-breaking research in the field of nanotechnology, specifically extracellular vesicles and perinatal-derived nanoparticles, has created a drug candidate that is the next frontier of regenerative biologic drug therapeutics. THE NEXT GENERATION OF BIOLOGIC MEDICINE PROGRAM UPDATES
0 kommentar(er)
